Neal Shore joins Ben Abbott of The Lancet to discuss the phase 3 POTOMAC trial of durvalumab plus BCG in BCG-naïve, high-risk non-muscle-invasive bladder cancer, which is being presented at ESMO 2025.

Click here to read the full article

Continue this conversation on social!

With the global burden of liver cancer growing, The Lancet has commissioned an international panel of experts to identify strategies to strengthen the prevention, surveillance, diagnosis, and treatment of liver cancer. Stephen Chan joins Ben Abbott of The Lancet to discuss the key messages of the Commission, which is published today on World Hepatitis Day.

Read the full Commission:

https://www.thelancet.com/commissions-do/hepatocellular-carcinoma?dgcid=buzzsprout_icw_podcast_lancethcc25_lancet

Continue this conversation on social!

Early detection of oesophageal adenocarcinoma improves outcomes. Patients with the precursor lesion, Barrett's oesophagus, are recommended to undergo regular endoscopic surveillance, a process that can be burdensome for patients and health services. 

Professor Rebecca Fitzgerald's team have developed a tool that may be able to improve Barrett's surveillance. She joins us to discuss her recent prospective real-world implementation study of capsule sponge risk stratification in Barrett’s oesophagus surveillance in the UK.

Read the full article:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01021-9/fulltext?dgcid=buzzsprout_icw_podcast_July_25_lancet

Continue this conversation on social!

Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, and Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, join Leon Terner to share some of their experiences, impressions and highlights from this year's American Society of Clinical Oncology (ASCO) conference. 

If you haven't already, be sure to listen to Vania's pre-ASCO predictions podcast here: https://www.buzzsprout.com/882697/episodes/17233167

Articles discussed in this podcast episode include:

Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study:

Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial:

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial:

#asco2025

Continue this conversation on social!

Changsong Qi joins Chloe Wilson and Ben Abbott of The Lancet to discuss their recently published phase 2 randomised controlled trial investigating Claudin-18 isoform 2-specific CAR T-cell therapy for previously treated advanced gastric or gastro-oesophageal junction cancer.

Read the full article:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_May_25_lancet

Continue this conversation on social!

Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, joins Gavin Cleaver to discuss what's being published at this year's American Society of Clinical Oncology (ASCO) meeting, what she's excited to see at the conference, and why ASCO is so important to the field.

Continue this conversation on social!

Francis Couturaud joins Chloe Wilson of The Lancet to discuss the RENOVE trial, which looks at assessing the efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants in patients in whom extended anticoagulation has been indicated.

Read the full paper: 

Continue this conversation on social!

This week, we discuss treatment approaches for uncomplicated appendicitis in children following the publication of a trial in our January 18th issue. Lead author Shawn St Peter, general paediatric surgeon and surgeon-in-chief at Children’s Mercy Hospital, Kansas City, spoke with Callam Davidson about the motivation behind the study, key findings, and what the results mean for clinical practice.

Continue this conversation on social!

Michael Heneka joins Chloe Wilson and Bea Gomez Perez-Nievas of The Lancet to discuss a therapeutics paper discussing the opportunities and challenges of passive anti-amyloid β immunotherapy in Alzheimer's disease.

Continue this conversation on social!

ROSHNI-2 was a multicentre, randomised controlled trial that investigated the efficacy of a culturally adapted, cognitive behavioural therapy-based intervention for postnatal depression in British south Asian women. Joining us to share their expertise and perspectives are chief investigator Professor Nusrat Husain, trial manager Farah Lunat, and service user representative Fehmida Motala.

Continue this conversation on social!